The study found that RGN-259 treatment promoted recovery of mucins and goblet cells, improved corneal integrity, increased tears, and reduced inflammation in a dry eye mouse model. Such ...

Clinical results in patients with NK treated with RGN-259 have previously demonstrated efficacy in a small number of patients (18) in the first phase 3 clinical trial (SEER-1), and two clinical ...